UNSPSC 51162200: Combination bronchodilators and respiratory agents

This classification denotes a) combination drugs that cause an increase in the expansion of a bronchus or bronchial tubes, hence the term BRONCHODILATORS; b) that treat disorders of the tubular and cavernous organs and structures, by means of which pulmonary ventilation and gas exchange between ambient air and the blood are brought about, or the respiratory system, hence the term RESPIRATORY AGENTS. Typical combination bronchodilator and respiratory agent constituents are acetaminophen, aminophylline, camphor, cetyl alcohol, chlorpheniramine, dextrose, ephedrine, and isoproterenol.

UNSPSC 51162200 Combination bronchodilators and respiratory agents is a Class code encompassing pharmaceutical products supplied through state and local cooperative purchasing agreements and institutional procurement channels. State and local governments procure these medications through multistate purchasing alliances and health system contracts to stock them across correctional facilities, public health clinics, emergency services, and other government-operated or government-supported healthcare settings. The solicitations under this code reflect the pharmaceutical supply chain architecture — manufacturers or authorized distributors propose products with specific National Drug Codes (NDC), strengths, dosage forms, and packaging, then supply through contracted wholesalers to end-user agencies. Issuing bodies include multistate cooperative purchasing entities administered by state procurement offices (such as the Minnesota Multistate Cooperative Purchasing Alliance), individual state health and human services departments, county health departments, and municipal health systems. The work is transactional — vendors establish pricing, maintain compliance with Drug Supply Chain Security Act (DSCSA) and current Good Manufacturing Practices (cGMP) standards, and sustain relationships with authorized distribution partners.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 seeking manufacturers and suppliers of generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota, Oregon, and other member states. The RFP closes March 26, 2026, with awards effective July 1, 2026; evaluation emphasizes price competitiveness (75 percent weight), compliance with administrative data formatting and EDI capability (5 percent each), fixed pricing transparency (10 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain $5 million commercial general liability and network security liability coverage, supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, or Morris & Dickson Co., LLC, and accept performance penalties of $200 to $1,500 per violation for reporting or onboarding failures. The contract term is two years for new responders with optional extensions, or alignment with existing expiration dates through June 30, 2028 for incumbents.